Drug Profile
Research programme: cancer vaccines - Pique Therapeutics
Alternative Names: PT-123; PT-128; PT-207Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pique Therapeutics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Head and neck cancer; Pancreatic cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (Parenteral)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (Parenteral)